Localisation of AMPK γ subunits in cardiac and skeletal muscles

Katalin Pinter · Robert T. Grignani · Hugh Watkins · Charles Redwood

Received: 4 July 2013 / Accepted: 30 August 2013 / Published online: 14 September 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract The trimeric protein AMP-activated protein kinase (AMPK) is an important sensor of energetic status and cellular stress, and mutations in genes encoding two of the regulatory γ subunits cause inherited disorders of either cardiac or skeletal muscle. AMPKγ2 mutations cause hypertrophic cardiomyopathy with glycogen deposition and conduction abnormalities; mutations in AMPKγ3 result in increased skeletal muscle glycogen. In order to gain further insight into the roles of the different γ subunits in muscle and into possible disease mechanisms, we localised the γ2 and γ3 subunits, along with the more abundant γ1 subunit, by immunofluorescence in cardiomyocytes and skeletal muscle fibres. The predominant cardiac γ2 variant, γ2-3B, gave a striated pattern in cardiomyocytes, aligning with the Z-disk but with punctate staining similar to T-tubule (L-type Ca2+ channel) and sarcoplasmic reticulum (SERCA2) markers. In skeletal muscle fibres AMPKγ3 localises to the I band, presenting a uniform staining that flanks the Z-disk, also coinciding with the position of Ca2+ influx in these muscles. The localisation of γ2-3B- and γ3-containing AMPK suggests that these trimers may have similar functions in the different muscles. AMPK containing γ2-3B was detected in oxidative skeletal muscles which had low expression of γ3, confirming that these two regulatory subunits may be coordinately regulated in response to metabolic requirements. Compartmentalisation of AMPK complexes is most likely dependent on the regulatory γ subunit and this differential localisation may direct substrate selection and specify particular functional roles.

Keywords AMPK · γ Subunits · Sub-cellular localisation · Cardiomyopathy

Introduction

AMPK regulates cellular energy homeostasis by monitoring the energy status of the cell (Hardie 2007). It is a hetero-trimeric complex (αβγ), α being the catalytic subunit. In mammals, there are two or three isoforms of each subunit (α1 and α2; β1 and β2; γ1, γ2 and γ3), each encoded by different genes (Hardie et al. 1998; Cheung et al. 2000). Differences in the tissue distribution of isoforms (Stapleton et al. 1997; Thornton et al. 1998; Turnley et al. 1999) and in muscle fibre type specific expression patterns have been reported (Durante et al. 2002; Winder et al. 2003; Mahlapuu et al. 2004). The regulatory γ subunits bind adenine nucleotides in the highly conserved nucleotide-binding domain consisting of four cystathionine-β-synthase (CBS) motifs. AMPK is allosterically activated when the AMP/ATP and ADP/ATP ratio increases; complexes containing the α2 and γ2 subunit isoforms are stimulated to a greater extent by AMP than those containing α1 and γ1 (Salt et al. 1998; Cheung et al. 2000; Oakhill et al. 2011), and those containing γ3 are least sensitive to AMP (Scott et al. 2004). The γ1 subunit is the most abundant and shows wide tissue expression, as does γ2 whereas the γ3 isoform is almost exclusively expressed in skeletal muscle (Lang et al. 2000; Barnes et al. 2004;
Mahlapuu et al. 2004; Yu et al. 2004). Transcription from different promoters of the gene encoding AMPKγ2 (PRKAG2) generates at least three transcripts in cardiomyocytes (Fig. 1): one comprising the nucleotide binding domain only (γ2-short) and two longer transcripts (γ2-long and γ2-3B) both consisting of the nucleotide binding domain plus an N-terminal extension of different length (Cheung et al. 2000; Lang et al. 2000; Pinter et al. 2012a). The γ2-3B subunit is the predominant γ2 form in heart along with γ2-short, and its expression in other tissues is low or negligible; γ2-long is poorly expressed in the heart (Cheung et al. 2000; Lang et al. 2000; Pinter et al. 2012a).

Mutations in PRKAG2 have been shown to cause cardiac hypertrophy with associated glycogen deposition, Wolff-Parkinson-White syndrome and conduction abnormalities (Blair et al. 2001; Gollob et al. 2001; Arad et al. 2002; Kim et al. 2009). All reported mutations are within the nucleotide-binding domain, and functional studies have suggested both that the basal level of activity is increased (Hamilton et al. 2001) and that nucleotide binding is lower or even abolished in the mutant protein resulting in impairment of AMPK activation (Steinberg and Kemp 2009). Interestingly, there is a reported mutation (R225Q) in γ3 occurring naturally in pig (Milan et al. 2000) and in human (R225W) (Costford et al. 2007); these mutations cause increased glycogen deposition in skeletal muscle in both cases, probably via increased glucose uptake rather than decreased glycogen utilisation (Andersson 2003). The amino acid affected by the γ3 mutation occupies the same position within the first CBS domain as the R302Q γ2 mutation.

The precise subcellular localisation of AMPK complexes within muscle cells is unclear. The β2 isoform, and hence trimers containing this subunit, was localized in the M-line in muscle fibres (Ponticos et al. 1998). In a different study, it was demonstrated that α1/γ1-containing AMPK is found in the Z-disk, apparently mediated by interaction of γ1 with plectin (Gregor et al. 2006), suggesting that, at least in this case, the regulatory subunit is responsible for AMPK compartmentalisation. In support of this, our work and function depends on their subcellular localisation that may be determined by the γ subunit. We have already demonstrated that AMPK complexes with distinct subunit compositions are compartmentalised and assigned for different cellular functions (Pinter et al. 2012b). In this study we provide further support for this notion by using immunofluorescence technique and detecting differential localisation of AMPK complexes with different γ subunits in mouse cardiomyocytes and in skeletal muscle fibres.

Methods

Animals and tissue collection

Ventricular cardiomyocytes were isolated from the heart C57BL/6 mice as described previously (Sears et al. 2003; Zhang et al. 2008); skeletal muscles (EDL, white quadriceps and soleus) were obtained from the same mouse strain.

Immunofluorescent staining and confocal microscopy

Isolated mouse ventricular cardiomyocytes in cell suspension were spun onto poly-Lys-coated slides in a Statspin cytofuge (600 rpm, 2 min). Cells were fixed in 4 % PFA and permeabilized in 0.2 % Triton-PBS for 30 min. Blocking was carried out with 5 % BSA in PBS. Bundles of skeletal muscle fibres were teased out in relaxing solution (10 mM EGTA, 5.6 mM MgCl2, 100 mM KCl, 20 mM imidazole, 5 mM ATP, pH 7.0; supplied with 10 mM creatine phosphate and 500 U/ml creatine kinase) onto poly-Lys-coated slides. Air-dried slides were rehydrated in PBS, then fixed and treated similarly to cardiomyocytes. Primary antibodies: rabbit anti-γ2 (γ2-C-terminal), 1:60 dilution (gift from D. Carling); rabbit anti-γ2-3B (G2-3B), 1:50 (Pinter et al. 2012a); rabbit anti-γ2-long (G2-L), 1:50 [polyclonal antibody G2-L was raised in goat against the KHL-conjugated peptide 1-20 of γ2-long (MDTKKKKEVSSPGGSSGKKN-C) by Harlan UK (Hill-Goat); mouse anti-myomesin, 1:30 dilution (gift from E. Ehler); mouse monoclonal anti-α-actinin (EA53), 1:500 dilution (Sigma); goat L-type Ca2+/CP τ1D (E-19), 1:50 dilution (Santa Cruz); goat SERCA2 (N-19), 1:50 dilution (Santa Cruz); mouse monoclonal anti-slow myosin heavy chain (BA-F8), 1:500

 Springer
dilution (DSHB). Primary antibodies were usually applied overnight at 4 °C.

The appropriate fluorescent conjugated secondary antibodies (Alexa Fluor Molecular Probes) were used in 1:400 dilution; both the primary and the secondary antibodies were diluted in 5% BSA/PBS. When it was possible, double staining was carried out. Cells were mounted using SlowFade Gold antifade reagent with DAPI (Invitrogen), however the nuclei were actually stained and imaged with To-Pro3/DNA (Invitrogen) and coloured in blue. Imaging was performed with a Leica TSC SP5 confocal laser-scanning microscope with a 63×, 1.4NA objective.

Results

Use of AMPKγ antibodies to localise AMPK complexes

AMPK is a trimeric complex and the subunits are not known to have any role as isolated proteins; therefore by detecting the γ subunits the subcellular localisation of the holoenzyme can be monitored. Differential localization of the γ2 protein variants is rather challenging. All γ2 variants share the entire sequence of γ2-short (Fig. 1) and therefore γ2-short cannot be selectively detected with antibodies. The available γ2 antibodies either recognise all three variants (if raised against sequence of the γ2 protein) or one (or both) of the longer forms (if raised against N-terminal sequences). The epitopes recognised by the three antibodies used in this study are mapped in Fig. 1. Antibody γ2C is a pan-γ2 antibody, with the immunogen being a short peptide at the C-terminus of all γ2 proteins; we have raised G2-L against the N-terminal peptide of 20 amino acids, and it exclusively detects γ2-long; and G2-3B, that only recognises γ2-3B (Pinter et al. 2012a).

Localisation of AMPKγ isoforms in mouse cardiomyocytes

The G2-3B antibody that selectively reacts with γ2-3B, revealed a principally striated pattern with some nuclear staining. The striations aligned with the Z-disk as shown by co-staining with the α-actinin antibody (Fig. 2A). However, the staining is considerably more punctate and less uniform than that of α-actinin (higher magnification in the second row, Fig. 2A), suggesting that AMPK with γ2-3B may associate with structures that align with the Z-disk, such as the T-tubules and sarcoplasmic reticulum (SR). We tested this using antibodies against markers of T-tubules (L-type Ca2+ channel) and SR (SR Ca2+-ATPase, SERCA2); both of these antibodies produced punctate staining, more similar to γ2-3B than to the uniform α-actinin pattern (Fig. 2B). The terminal cisternae of the SR form irregular dyads in cardiomyocytes, hence the punctate staining along the Z-disk. In contrast to the T-tubules of skeletal muscle, those of the cardiomyocytes can run in a longitudinal as well as in a transverse direction (Soeller and Cannell 1999) and the punctate staining pattern with the T-tubule marker may arise from the longitudinal branches of the system. Schematic diagram of SR and T-tubular system in cardiomyocyte is shown in Fig. 2C.

The staining for the minority γ2-long variant produced a mainly Z-disk striated pattern, similar to the γ2-3B staining, along with some staining at the M-line (Fig. 3A). The C-terminal γ2C antibody, which detected three bands in Western blots of mouse heart tissue (Pinter et al. 2012a) produced clear staining of both the Z-disk and M-line regions (Fig. 3A). Whether the M-line signal reflects the presence of γ2-long variant (G2-L antibody detected some γ2-long protein in the M-line), or the γ2-short variant is unclear and is discussed later.

The γ1 protein was present in the Z-disk (Fig. 3B). This is consistent with the earlier report of its localisation in differentiated mouse myotubes, possibly recruited by binding plectin, a Z-disk component (Gregor et al. 2006). No nuclear staining was observed with the γ1 antibody in cardiomyocytes.

Localisation of AMPKγ isoforms in mouse skeletal muscles

The γ3 regulatory subunit is mainly expressed in white, glycolytic fibres of adult skeletal muscle (Mahlapuu et al. 2004). The majority of fibres is type IIB in white quadriceps muscle of mouse (~94%; fast, glycolytic fibres) and large proportion of fibres in EDL are also glycolytic (Bloemberg and Quadrilatero 2012). We isolated and stained bundles of fibres from EDL and from white quadriceps muscles and found γ3 staining around the Z-disk (Fig. 4A), but it is broader than the γ1 staining and some γ3 staining is also detectable in the nucleus; nuclear staining is more obvious in Fig. 4B. The γ3 staining appears as a highly uniform doublet along the Z-disk (Fig. 4B); the depicted, well-organised structure can be seen in the enlarged segment of the image.
The T-tubule marker (L-type Ca\(^{2+}\) channel antibody) and the SERCA2 antibody decorate the T-tubule/SR system in skeletal muscle fibres (Fig. 5C). Since the terminal cisternae of the SR form triads with the T-tubule in skeletal muscle, the pattern is very regular, rather similar to staining pattern shown for \(\gamma_3\) (Fig. 5B).

We have previously detected \(\gamma_3\) expression in the developing mouse heart; this declines after birth and appears to be “replaced” by \(\gamma_2\)-3B expression (Pinter et al. 2012a). The \(\gamma\) subunit “switch” seems to coincide with metabolic changes: the embryonic heart is mainly glycolytic while the adult heart is oxidative. We therefore tested whether the oxidative skeletal muscle fibres contained AMPK \(\gamma_2\)-3B. When EDL or white quadriceps fibres were stained with the \(\gamma_2\)-3B antibody, we detected, though infrequently, fibres that were stained with \(\gamma_2\)-3B antibody; the staining pattern was similar to the \(\gamma_3\) staining (Fig. 5A). In contrast, the occurrence of \(\gamma_2\)-3B-stained fibres in soleus muscle was higher and imaging is shown in Fig. 5B. The pattern of \(\gamma_2\)-3B staining resembles that of \(\gamma_3\) (see enlarged segment, Fig. 5B), suggesting that the two subunits occupy similar positions. No \(\gamma_2\)-3B staining was detected in the nuclei (Fig. 5A).

Interestingly, skeletal myopathy has been observed in patients with \textit{PRKAG2} mutations (Murphy et al. 2005); ragged red fibres with excess mitochondria were detected but skeletal muscle biopsies of patients presented little glycogen accumulation.

Although a large proportion of fibres are slow oxidative type I in mouse soleus muscle (\(\sim 30\%\)), about 50% of the population are fast oxidative type IIA fibres (Bloemberg and Quadrilatero 2012). As type I fibres can be identified by their \(\beta\) myosin heavy chain content, therefore we performed double staining with a slow myosin heavy chain antibody (MHC-I) and with G2-3B antibody. The monoclonal MHC-I antibody recognizes both \(\alpha\) and \(\beta\) myosin heavy chains and decorated cardiomyocytes as expected (Fig. 6A). Some soleus fibres react with both the MHC-I and with the \(\gamma_2\)-3B antibodies but not all \(\gamma_2\)-3B-reactive fibres are co-stained with MHC-I (Fig. 6B). The fibres that are not stained by the slow myosin antibody most likely are the fast oxidative type II fibres.
Fig. 3 Subcellular localisation of γ2 and γ1 in mouse ventricular cardiomyocytes.  
(A) Staining patterns produced by antibodies to γ2-long (G2-L) and by a pan-γ2 antibody (γ2C). The strongest staining is around the Z-disk with these antibodies; antibodies G2-L and γ2C detect γ2 protein in the M-line.  
(B) Localisation of AMPK γ1 in the Z-disk by co-staining the cells with the Z-disk marker α-actinin antibody.

Fig. 4 Immunofluorescence staining of mouse skeletal muscle fibres.  
(A) Localisation of the AMPK γ subunits in skeletal muscle fibres. AMPK with γ1 is in the Z-disk; the γ3 staining is more punctate around the Z-disk. There is γ3 staining in the nucleus. (B) The staining pattern for γ3 appears to be a very regular doublet flanking the Z-disk (enlargement of the boxed area, double green arrows). Nuclear staining with the γ3 antibody is very prominent. Marker for the Z-disk is γ1, and myomesin for the M-line. (C) Staining pattern of the T-tubules/SR system is similar to the γ3 staining. (A,C) EDL muscle fibres; (B) White quadriceps fibres.
Discussion

In mouse cardiomyocytes, the predominant AMPK γ2 protein, γ2-3B, was shown to give patchy Z-disk staining and was also found in the nuclei. The punctate Z-disk staining was similar to the T-tubule and SR markers, L-type Ca\(^{2+}\) channel and SERCA2 respectively. Staining with a pan-γ2 antibody suggested additional M-line localisation of either the γ2-short or γ2-long variants; the latter was confirmed with a γ2-long-specific antibody. Since the
affinity of the γ2C antibody is the same for each γ2 protein, the higher staining intensity in the Z-disk may reflect the presence of the γ2-short, which is the second most abundant γ2 protein in cardiomyocytes after γ2-3B (Pinter et al. 2012a). The AMPK γ2 variants thus appear to localize to different sarcomeric positions in cardiomyocytes.

Our earlier work has shown that AMPK can phosphorylate cardiac troponin I, both in vitro and in vivo, and that this phosphorylation modulates the myofilament Ca²⁺-sensitivity (Oliveira et al. 2012). This finding was initiated by the identification of the interaction of cardiac troponin I with a fragment containing the N-terminal 273 amino acids of AMPKγ2-long by Yeast-Two-Hybrid screening of a human cardiac cDNA library. However, γ2-long and γ2-3B have a common segment in their N-terminal extension, and since there is much more γ2-3B protein than γ2-long in cardiomyocytes (Pinter et al. 2012a), that function may be linked to AMPK containing γ2-3B. Given that there is no apparent staining throughout the I band, it is possible that AMPK is recruited to phosphorylate cardiac troponin I and mobilised from its position around the Z-disk upon activation.

The γ1 protein was localised at the Z-disk in cardiomyocytes. AMPK with the γ1 isoform is known to be anchored by plectin to the Z-disk in differentiated myocytes (Gregor et al. 2006) and our observation is consistent with this. The γ2-short, similarly to γ1, only contains the nucleotide-binding domain and the highly conserved segment close to its N-terminus to where the β subunit binding-site was localised (Viana et al. 2007). We have reported that γ2-short is largely replaced by γ1 during cardiogenesis (Pinter et al. 2012a), suggesting partially or entirely overlapping function for the two proteins and that may support the Z-disk localisation of γ2-short.

Interestingly, the Z-disk staining with the γ1 antibody resembles the subcellular positions of glycogen synthase (GS) that is regulated by AMPK (Prats et al. 2005; Bendayan et al. 2009); glycogen particles are also linked to the cytoskeleton and so are the glycogen-metabolising enzymes (Gregor et al. 2006; Graham et al. 2010). Therefore it is plausible to presume that AMPK with γ1 is involved in the regulation of glycogen metabolism along with AMPK containing the γ2-short subunit.

Both γ2-3B and γ3, in cardiac and skeletal muscle respectively, are present along the Z-disk and in the I band; both staining patterns closely resemble the respective T-tubule/SR structures. The different appearance of γ2-3B and γ3 staining reflects the structural differences of the T-tubules/SR structures in cardiac and skeletal muscle. In cardiomyocytes, the T-tubules are aligned with the Z-disk but a set of two T-tubules, flanking the Z-disk is present in the I band of skeletal muscle sarcomeres. In cardiac muscle, the arrangement of the terminal cisternae of SR is not as regular as in skeletal muscle, therefore diads flanking the Z-disk are formed instead of triads. The structure of the T-tubule system is also complex, with irregular branching in heart (Soeller and Cannell 1999).

Given their apparently common T-tubule/SR localisation, is there any indication that AMPK with γ2-3B or γ3 have similar functions? A point mutation in γ3 causes glycogen accumulation in skeletal muscle; the cause of this is not the activation of glycogen synthase or decreased glycogen utilization but increased glucose uptake (Andersson 2003). This mutation is in the first CBS domain, in the exact position as one of the γ2 mutations is; the consequence of the γ2 mutation is glycogen deposition in cardiac tissue (Gollob et al. 2001; Gollob 2003). The embryonic heart is more glycolytic but becomes more...
oxidative during differentiation; in parallel, there is an apparent switch from \( \gamma 3 \) to \( \gamma 2\)-3B expression in the developing heart (Pinter et al. 2012a). Glucose transport is mainly mediated by GLUT1 and GLUT4 in cardiomyocytes (Stanley et al. 1997) and myocardial AMPK activation and subsequent GLUT-4 translocation to the sarcolemma was reported in rat (Russell et al. 1999). The sodium/glucose cotransporter (SGLT1) is also expressed in cardiomyocytes (Boncompagni et al. 2009). The expression of SGLT1 (Sopjani et al. 2010).

In skeletal muscle, \( \alpha 2/\beta 2/\gamma 3 \) complexes become preferentially activated during exercise (Birk and Wojtaszewski 2006); \( \alpha 2\)-AMPK was identified as an endoplasmic reticulum (ER) stress suppressor as its activation maintains SERCA activity and intracellular \( \text{Ca}^{2+} \) homeostasis (Dong et al. 2010). The expression \( \gamma 3 \) is restricted to glycolytic fast fibres; oxidative fibres (slow or fast) seem to contain \( \gamma 2\)-3B. Mitochondria are tethered to the SR in both skeletal muscle fibres and in cardiomyocytes (Boncompagni et al. 2009) where we detected \( \gamma 2\)-3B. It has been reported that AMPK phosphorylates PGC1\( \alpha \) and instead of affecting the mitochondrial oxidative capacity it stimulate mitochondrial biogenesis (Jager et al. 2007). A \( \text{PRKAG2} \) mutation was shown to cause myopathy in red muscle (Murphy et al. 2005) and ragged red fibres were observed with mitochondrial accumulation but without substantial glycogen deposition. This observation also supports our finding that \( \gamma 2\)-3B is only expressed in oxidative muscle (cardiomyocytes, slow type I and fast type II skeletal muscle fibres), however we have not done the thorough fibre type matching.

Furthermore, several ion channels are regulated by AMPK, some of them by direct phosphorylation (reviewed by Andersen and Rasmussen 2012). In a recent study AMPK phosphorylation of the voltage-gated Kv2.1-channel was demonstrated in neurons, where AMPK activation reduced excitability to conserve energy (Ikeematsu et al. 2011). Kv2.1 is present in all part of the transverse and axial tubule system in cardiomyocytes (O’Connell et al. 2008). Ion channel down-regulation by AMPK has been reported; one of them is the KCNQ1 potassium channel. KCNQ1 ubiquitination is promoted by AMPK activation via the ubiquitin-protein ligase, Nedd4-2 in kidney cells (Alzamora et al. 2010). KCNQ1 is expressed in cardiomyocytes, where its abnormal trafficking was linked to hereditary long QT syndrome (Wilson et al. 2005). AMPK associated with the T-tubules may regulate ion transport, contributing perhaps to conductive irregularities that accompany cardiac hypertrophy caused by \( \text{PRKAG2} \) mutations.

In summary, we have demonstrated AMPK compartmentalisation in cardiomyocytes and in skeletal muscle fibres and showed that differential localisation of the different AMPK complexes is most likely governed by the regulatory subunits, either by the different \( \gamma \) isoforms or by the variants of \( \gamma 2 \). By compartmentalisation, the different AMPK complexes are most probably assigned different functions. Mutation in the \( \gamma 2 \) proteins would alter these functions; as a consequence, this could trigger mechanisms to cause the different aspects of the cardiac disease (hypertrophy, conductive disorder, glycogen deposition). However, further studies needed to understand the importance and the dynamics of the compartmentalisation of the \( \gamma 2\)-AMPK complexes, focusing on specific interactions in each location. The need for isoform-selective activation of AMPK to develop cardioprotective therapies has been highlighted in a recent review article (Kim and Tian 2011) and protein–protein interaction studies could result in new drug designs that acts specifically on \( \gamma 2\)-AMPK complexes to ameliorate the disease caused by the \( \text{PRKAG2} \) mutations.

Acknowledgments We thank Henrik Isackson for the preparation of skeletal muscle fibres. This work was supported by the British Heart Foundation and the Wellcome Trust Functional Genomics Initiative. R. T. Grignani was sponsored by the MBBS-PhD Programme (Agency for Science, Technology and Research, Singapore and School of Medicine, National University Singapore).

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Alzamora R, Gong F, Rondanino C, Lee JK, Smolak C, Pastor-Soler NM, Hallos KR (2010) AMP-activated protein kinase inhibits KCNQ1 channels through regulation of the ubiquitin ligase Nedd4-2 in renal epithelial cells. Am J Physiol Renal Physiol 299(6):F1308–F1319

Andersen MN, Rasmussen HB (2012) AMPK: a regulator of ion channels. Commun Integr Biol 5(5):480–484

Andersson L (2003) Identification and characterization of AMPK gamma 3 mutations in the pig. Biochem Soc Trans 31(Pt 1):232–235

Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, Seidman CE (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109(3):357–362

Banerjee SK, Magaffin KR, Pastor-Soler NM, Ahmad F (2009) SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84(1):111–118

Barnes BR, Marklund S, Steiler TL, Walter M, Hjalm G, Amarger V, Mahlapuu M, Leng Y, Johansson C, Galuska D, Lindgren K, Abrink M, Stapleton D, Zierath JR, Andersson L (2004) The 5’-AMP-activated protein kinase gamma3 isoform has a key role in...
carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem 279(37):38441–38447
Bendayan M, Londono I, Kemp BE, Hardie GD, Ruderman N, Prentki M (2009) Association of AMP-activated protein kinase subunits with glycojen particles as revealed in situ by immunoelectron microscopy. J Histochem Cytochem 57(10):963–971
Birk JB, Wojtaszewski JF (2006) Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol 577(Pt 3):1021–1032
Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H (2001) Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10(11):1215–1220
Bloomberg D, Quadrilatero J (2012) Rapid determination of myosin heavy chain expression in rat, mouse, and human skeletal muscle using multicolor immunofluorescence analysis. PLoS One 7(4):e35273
Boncompagni S, Rossi AE, Micaroni M, Beznoussenko GV, Polishock RS, Dirksen RT, Protasi F (2009) Mitochondria are linked to calcium stores in striated muscle by developmentally regulated tethering structures. Mol Cell Biol 20(3):1058–1067
Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (2000) Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 346 (Pt 3):659–669
Costford SR, Kavaslar N, Ahituv N, Chaudhry SN, Schackwitz WS, Dentl C, Pennacchio LA, McPherson R, Harper ME (2007) Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle. PLoS One 2(9):e903
Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC, Zou MH (2010) Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 121(6):792–803
Durante PE, Mustard KJ, Park SH, Winder WW, Hardie DG (2002) Effects of endurance training on activity and expression of AMP-activated protein kinase isoforms in rat muscles. Am J Physiol Endocrinol Metab 283(1):E178–E186
Eisenberg BR, Kuda AM, Peter JB (1974) Stereological analysis of the granule and its proteins. Acta Physiol (Oxf) 199(4):489–498
Gregor M, Zeold A, Oehlerl S, Marobela KA, Fuchs P, Weigel G, Hardie DG, Wiche G (2006) Plectin scaffolds recruit energy-controlling AMP-activated protein kinase (AMPK) in differentiated myofibres. J Cell Sci 119(Pt 9):1864–1875
Hamilton SR, Stapleton D, O’Donnell JB Jr, Kung JT, Dalal SR, Kemp BE, Witters LA (2001) An activating mutation in the gamma subunit of the AMP-activated protein kinase. FEBS Lett 500(3):163–168
Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8(10):774–785
Hardie DG, Carling D, Carlson M (1998) The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67:821–855
Ikematsu N, Dallas ML, Ross FA, Lewis RW, Rafferty JN, David JA, Suman R, Peers C, Hardie DG, Evans AM (2011) Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability. Proc Natl Acad Sci USA 108(44):18132–18137
Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104(29):12017–12022
Katz AM (1975) Congestive heart failure: role of altered myocardial cellular control. N Engl J Med 293(23):1184–1191
Kim M, Tian R (2011) Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol 51(4):548–553
Kim AS, Miller EJ, Young LH (2009) AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol (Oxf) 196(1):37–53
Lang T, Yu L, Tu Q, Jiang J, Chen Z, Xin Y, Liu G, Zhao S (2000) Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5’-AMP-activated protein kinase, to human chromosome 7q36. Genomics 70(2):258–263
Mahlapuu M, Johansson C, Lindgren K, Hjalmarsson B, Broock A, Zierath JR, Andersson L, Marklund S (2004) Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. Am J Physiol Endocrinol Metab 286(2):E194–E200
Milan D, Deon JT, Loofit C, Amargar V, Robic A, Thelander M, Rogel-Gaillard C, Paul S, Iannuccelli N, Rask L, Ronne H, Lundstrom K, Reinsch N, Gellin J, Kalm E, Roy PL, Chardon P, Andersson L (2000) A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288(5469):1248–1251
Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, Syrris P, Gorman G, Farrell M, Holton JLA, Hannah MG, Hughes S, Elliott PM, Macrae CA, McKenna WJ (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45(6):922–930
Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S, Kemp BE (2011) AMPK is a direct adenylyl charge-regulated protein kinase. Science 332(6036):1433–1435
O’Connell KM, Mines SJ, Itasaki N, Laskey RA, Swenson T, Yumita K, Shinozaki S, O’Connell KM, Whitesell JD, Tamkun MM (2008) Localization and mobility of the delayed-rectifier K+ channel Kv1.5 in adult cardiomyocytes. J Am Heart Assoc 29(1):H229–H237
Olivera SM, Zhang YH, Sancho Solis R, Isackson H, Bellahcene M, Yavari A, Pinter K, Davies JD, Ge Y, Ashrafian H, Walker JW, Carling D, Watkins H, Casadei B, Redwood C (2012) AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res 110(9):1192–1201
Pinter K, Grignani RT, Czibik G, Farza H, Watkins H, Redwood C (2012a) Embryonic expression of AMPK gamma subunits and the identification of a novel gamma2 transcript variant in adult heart. J Mol Cell Cardiol 53(3):342–349
Pinter K, Jeffersson A, Czibik G, Watkins H, Redwood C (2012b) Subunit composition of AMPK trimers present in the cytoisometric apparatus: implications for drug target identification. Cell Cycle 11(5):917–921
Ponticos M, Lu QL, Morgan JE, Hardie DG, Partridge TA, Carling D (1998) Dual regulation of the AMP-activated protein kinase
provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J 17(6):1688–1699
Prats C, Cadefau JA, Cusso R, Qvortrup K, Nielsen JN, Wojtaszewski JF, Hardie DG, Stewart G, Hansen BF, Ploug T (2005) Phosphorylation-dependent translocation of glycogen synthase to a novel structure during glycogen resynthesis. J Biol Chem 280(24):23165–23172
Russell RR 3rd, Bergeron R, Shulman GI, Young LH (1999) Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277(2 Pt 2):H643–H649
Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG (1998) AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 334(Pt 1):177–187
Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, Hardie DG (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 113(2):274–284
Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S, Wallis HL, Neubauer S, Terrar DA, Casadei B (2003) Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 92(5):e52–e59
Soeller C, Cannell MB (1999) Examination of the transverse tubular system in living cardiac rat myocytes by 2-photon microscopy and digital image-processing techniques. Circ Res 84(3):266–275
Sopjani M, Bhavsar SK, Fraser S, Kemp BE, Foller M, Lang F (2010) Regulation of Na+-coupled glucose carrier SGLT1 by AMP-activated protein kinase. Mol Membr Biol 27(2-3):137–144
Stanley WC, Hall JL, Hacker TA, Hernandez LA, Whitesell LF (1997) Decreased myocardial glucose uptake during ischemia in diabetic swine. Metabolism 46(2):168–172
Stapleton D, Woollett E, Mitchellll KL, Nicholl JK, Fernandez CS, Michell BJ, Witters LA, Power DA, Sutherland GR, Kemp BE (1997) AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett 409(3):452–456
Steinberg GR, Kemp BE (2009) AMPK in Health and Disease. Physiol Rev 89(3):1025–1078
Thornton C, Snowden MA, Carling D (1998) Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem 273(20):12443–12450
Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF (1999) Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J Neurochem 72(4):1707–1716
Viana R, Towler MC, Pan DA, Carling D, Viollet B, Hardie DG, Sanz P (2007) A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits. J Biol Chem 282(22):16117–16125
Wilson AJ, Quinn KV, Graves FM, Bitner-Glindzicz M, Tinker A (2005) Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 67(3):476–486
Winder WW, Hardie DG, Mustard KJ, Greenwood LJ, Paxton BE, Park SH, Rubink DS, Taylor EB (2003) Long-term regulation of AMP-activated protein kinase and acetyl-CoA carboxylase in skeletal muscle. Biochem Soc Trans 31(Pt 1):182–185
Yu H, Fujii N, Hirshman MF, Pomerleau JM, Goodyear LJ (2004) Cloning and characterization of mouse S5'-AMP-activated protein kinase gamma3 subunit. Am J Physiol Cell Physiol 286(2):C283–C292
Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A, Kranias EG, Casadei B (2008) Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res 102(2):242–249